What Analysts Recommend for Biogen in June 2017
Biogen revenue trends
In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth. Wall Street analysts have estimated that Biogen’s revenue will be around $11.4 billion in 2017. Globally, ~38% of all multiple sclerosis (or MS) patients are treated with Biogen products. The company’s MS franchise generated revenues of around $2.2 billion in 1Q17.
In 1Q17, Biogen reported revenues of around $2.8 billion, which is 3% growth on a YoY basis and a 2% decline on a quarter-over-quarter basis. Biogen’s revenue growth may boost the share prices of the Health Care Select Sector SPDR Fund (XLV). Biogen holds ~2% of XLV’s total portfolio holdings.
Interested in ABBV? Don't miss the next report.
Receive e-mail alerts for new research on ABBV
In 1Q17, Biogen reported GAAP R&D expenses of around $423 million, which is 15% of total revenues. The company reported SP&A expenses of around $499 million, which is ~18% of total revenues.
The above graph represents analysts’ ratings for Biogen from June 2016 to June 2017.
A total of 27 analysts are covering Biogen in June 2017. Seven analysts recommended a “strong buy,” while nine analysts recommended a “buy.” Eleven analysts recommended a “hold.” About 59% of the analysts recommended some form of “buy.”
A total of 21 analysts were covering AbbVie (ABBV) in June 2017. Three analysts suggested a “strong buy,” seven suggested a “buy,” 11 recommended a hold, and none recommended a “sell” or “strong sell.” Around 48% of the analysts analyzing AbbVie suggested some form of “buy.”
In June 2017, 27 analysts were analyzing Sanofi (SNY). Four analysts recommended a “strong buy” while seven analysts recommended a “buy.” Fourteen analysts recommended a “hold” while two analysts recommended a “sell.” None of the analysts analyzing Sanofi recommended a “strong sell.” Around 41% of analysts suggested some form of “buy.”
32 analysts were analyzing Novartis (NVS) in June 2017. Six analysts recommended a “strong buy,” eight recommended a “buy,” 16 recommended a “hold,” while two recommended a “sell” for Novartis. None of the analysts suggested a “strong sell.” Around 43% of analysts recommended some form of “buy.”